Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
P1.01 - Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 80
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-001 - Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial
09:30 - 09:30 | Presenter: D. Ross Camidge
- Abstract
Loading... -
+
P1.01-040 - Clinical Utility of Plasma-Based NGS for Advanced-Stage NSCLC Patients with Insufficient or Unavailable Tumor Tissue
09:30 - 09:30 | Author(s): J. Zugazagoitia
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 13
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.04-001 - Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
09:30 - 09:30 | Presenter: Helena Yu
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 12
- Moderators:Ravi Salgia
- Coordinates: 10/16/2017, 11:00 - 12:30, Room 511 + 512
-
+
MA 02.02 - Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
11:05 - 11:10 | Author(s): B.P. Levy
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MS 02 - Ethnic Differences: Biology or Myth
- Type: Mini Symposium
- Track: Regional Aspects/Health Policy/Public Health
- Presentations: 6
- Moderators:R. Natale
- Coordinates: 10/16/2017, 11:00 - 12:30, Room 501
-
+
MS 02.04 - Targeted Agents and Immunotherapy: Efficacy and Toxicity Difference According to Ethnicity
11:45 - 12:00 | Presenter: Luis Paz-Ares
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA 05 - Immuno-Oncology: Novel Biomarker Candidates
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Presentations: 15
- Moderators:Yoichi Nakanishi
- Coordinates: 10/16/2017, 15:45 - 17:30, Room 303 + 304
-
+
MA 05.03 - The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC
15:55 - 16:00 | Presenter: Laura Mezquita
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA 05 - Next Generation TKI
- Type: Oral
- Track: Advanced NSCLC
- Presentations: 9
- Moderators:James Chih-Hsin Yang
- Coordinates: 10/16/2017, 15:45 - 17:30, Room 301 + 302
-
+
OA 05.05 - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
16:30 - 16:40 | Presenter: Myung-Ju Ahn
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 14
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.04-002 - CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
09:30 - 09:30 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf
- Abstract
Loading... -
+
P2.04-008 - ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy
09:30 - 09:30 | Author(s): A. Farago
- Abstract
Loading... -
+
P2.04-010 - Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung
09:30 - 09:30 | Presenter: Jonathan W Riess
- Abstract
Loading... -
+
P2.04-013 - ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
09:30 - 09:30 | Author(s): Johan F. Vansteenkiste
- Abstract
Loading...
-
+
P2.07 - Immunology and Immunotherapy
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 65
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-060 - Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients
09:30 - 09:30 | Presenter: Laura Mezquita
- Abstract
Loading...
-
+
MA 12 - Circumventing EGFR Resistance
- Type: Mini Oral
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:Wan Ling Tan
- Coordinates: 10/17/2017, 11:00 - 12:30, F205 + F206 (Annex Hall)
-
+
MA 12.02 - Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
11:05 - 11:10 | Presenter: Gee-Chen Chang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA 07 - ALK, ROS and HER2
- Type: Mini Oral
- Track: Advanced NSCLC
- Presentations: 16
- Moderators:Robert C. Doebele
- Coordinates: 10/17/2017, 15:45 - 17:30, Room 316
-
+
MA 07.03 - Incidence, Predictors and Prognostic Significance of Thromboembolic Events in Patients with Advanced Alk-Rearranged NSCLCs
15:55 - 16:00 | Presenter: Jon Zugazagoitia
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
